尿激酶与低分子肝素钙联用治疗急性心肌梗死临床研究  

Clinical Study of Urokinase Combined With Low Molecular Weight Heparin Calcium in the Treatment of Acute Myocardial Infarction

作　　者：王彬[1] 王增琛[1] 

机构地区：[1]鸡西市人民医院心内科,黑龙江鸡西158100

出　　处：《中国卫生标准管理》2016年第6期77-78,共2页China Health Standard Management

摘　　要：目的剖析急性心肌梗死联合运用尿激酶和低分子肝素钙的疗效。方法将急性心肌梗死76例随机等分成实验组与对照组。两组行常规治疗,实验组同时运用尿激酶静脉溶栓疗法。结果实验组心脏事件发生率为10.53%、冠状动脉再通率为71.05%、死亡率为2.63%,对照组依次为36.84%、34.21%、15.79%。组间差异有统计学意义,P<0.05。结论将尿激酶和低分子肝素钙联合用于急性心肌梗死中,既利于冠状动脉的再通,又能预防心脏事件。Objective To analyze the curative effect of urokinase combined with low molecular weight heparin calcium in the treatment of acute myocardial infarction. Methods 76 cases of acute myocardial infarction（ami）were randomly divided into experimental group and control group,using regular treatment in both groups. The experimental group at the same time using urokinase intravenous thrombolysis therapy. Results The incidence of cardiac events was 10.53%,the rate of coronary artery was 71.05%,mortality was 2.63% in experimental group. 36.84%,34.21% and 15.79% in control group. There were significant difference between groups,P〈0.05. Conclusion Low molecular heparin calcium and urokinase to joint used in acute myocardial infarction（ami）,not only conducive to coronary artery recanalization,but also prevent heart attacks.

关 键 词：低分子肝素钙 急性心肌梗死 冠状动脉 

分 类 号：R542.2[医药卫生—心血管疾病]